Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.81 |
| ▸ | CCND1 | P24385 | 4/20 | 0.81 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4863420 | 0.94 | CDK4 (0.78) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL3616878 | 0.86 | CDK4 (0.76) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL11366447 | 0.82 | CDK4 (1.00) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL4554026 | 0.81 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL18911783 | 0.81 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL30495581 | 0.81 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL8656866 | 0.81 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL29571527 | 0.81 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL5661674 | 0.81 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL2410943 | 0.81 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317706-A1 | HNF4alpha MODULATORS AND METHODS OF USE | BUMHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100286220-A1 | HNF4alpha ANTAGONISTS AND METHODS OF USE | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010127264-A2 | HNF4α ANTAGONISTS AND METHODS OF USE | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127246-A2 | HNF4 MODULATORS AND METHODS OF USE | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-1996033171-A1 | 1H-PYRROL-1-YL AND 1H-INDOL-1-YL ARYL SULPHONES, PROCESSES FOR THEIR PREPARATION AND USE FOR THE THERAPY OF HIV-1 INFECTIONS | ISTITUTO SUPERIORE DI SANITÁ (IT) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996033171-A1 | 1H-PYRROL-1-YL AND 1H-INDOL-1-YL ARYL SULPHONES, PROCESSES FOR THEIR PREPARATION AND USE FOR THE THERAPY OF HIV-1 INFECTIONS | ISTITUTO SUPERIORE DI SANITÁ (IT) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317706-A1 | HNF4alpha MODULATORS AND METHODS OF USE | HNF4A, NCOA4, NR4A3 | CDK4 202/4885CCND1 3990/4885HTR2A 948/4885 |
| US-20100286220-A1 | HNF4alpha ANTAGONISTS AND METHODS OF USE | HNF4A, NCOA4, NR1H4 | CDK4 156/4885CCND1 3113/4885HTR2A 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.